Interferon-β Is More Potent Than Interferon-α in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Background:The prognosis of advanced hepatocellular carcinoma (HCC) is extremely poor, but promising effects of chemotherapies combined with interferon (IFN) have been reported.
Methods:To develop more effective combination therapies for HCC, we compared the antiproliferative effects of IFN-α and IFN-β in combination with various cytotoxic drugs on hepatoma cell lines using MTT assay and isobologram analysis.
Results:IFN-β was more potent than IFN-α in inhibiting the cell growth of all cell lines (P < .05, two-way ANOVA). PLC/PRF/5 was more sensitive to either IFN, than HLE and HuH7. Cell growth of all cell lines was inhibited in a dose-dependent manner by 5-fluorouracil (5-FU), cisplatin (CDDP), and doxorubicin (DOX), but the sensitivities of these cells were considerably different. As for IFN-α, synergistic effects were observed when combined with 5-FU and DOX on PLC/PRF/5 cells only, whereas IFN-β showed synergistic effects with 5-FU and CDDP on HuH7 and PLC/PRF/5 cell lines.
Conclusion:The spectra of the antiproliferative activity and synergistic effect of IFN-β when combined with anticancer drugs are more potent than those of IFN-α. Combinations of IFN-β and anticancer drugs may provide a better treatment of HCC when combinations with IFN-α are ineffective.
- Okuda K. Hepatocellular carcinoma. J Hepatol 2000; 32 (suppl 1): 225–37. CrossRef
- Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Seminin Liver Dis 1999; 19: 271–85. CrossRef
- Anthony PP. Hepatocellular carcinoma: an overview. Histopathology 2001; 39: 109–18. CrossRef
- Teo EK, Fock KM. Hepatocellular carcinoma: an Asian perspective. Dig Dis 2001; 19: 263–8. CrossRef
- Johnson PJ. Hepatocellular carcinoma: is current therapy really altering outcome? Gut 2002; 51: 459–62. CrossRef
- Leung TW, Tang AM, Zee B, et al. Factors predicting response and survival in 149 patients with unresectable hepatocellular carcinoma treated by combination cisplatin, interferon-α, doxorubicin and 5-fluorouracil chemotherapy. Cancer 2002; 94: 421–7. CrossRef
- Urabe T, Kaneko S, Matsushita E, Unoura M, Kobayashi K. Clinical pilot study of intrahepatic arterial chemotherapy with methotrexate, 5-fluorouracil, cisplatin and subcutaneous interferon-α-2b for patients with locally advanced hepatocellular carcinoma. Oncology 1998; 55: 39–47. CrossRef
- Sakon M, Nagano H, Dono K, et al. Combined intraarterial 5-fluorouracil and subcutaneous interferon-α therapy for advanced hepatocellular carcinoma with tumor thrombi in the major portal branches. Cancer 2002; 94: 435–42. CrossRef
- Stuart K, Tessitore J, Huberman M. 5-Fluorouracil and α-interferon in hepatocellular carcinoma. Am J Clin Oncol 1996; 19: 136–9. CrossRef
- Stark GR, Kerr IM, Williams BR, Silverman RH, Schreiber RD. How cells respond to interferons. Annu Rev Biochem 1998; 67: 227–64. CrossRef
- Berenbaum MC. Criteria for analyzing interactions between biologically active agents. Adv Cancer Res 1981; 35: 269–335. CrossRef
- Von Hoff DD, Casper J, Bradley E, Sandbach J, Jones D, Makuch R. Association between human tumor colony-forming assay results and response of an individual patient’s tumor to chemotherapy. Am J Med 1981; 70: 1027–41. CrossRef
- Horikoshi T, Fukuzawa K, Hanada N, et al. In vitro comparative study of the antitumor effects of human interferon-α, β and γ on the growth and invasive potential of human melanoma cells. J Dermatol 1995; 22: 631–6.
- Giandomenico V, Vaccari G, Fiorucci G, et al. Apoptosis and growth inhibition of squamous carcinoma cells treated with interferon-α, IFN-β and retinoic acid are associated with induction of the cyclin-dependent kinase inhibitor p21. Eur Cytokine Netw 1998; 9: 619–31.
- Coradini D, Biffi A, Pirronello E, Di Fronzo G. The effect of α-, β- and γ-interferon on the growth of breast cancer cell lines. Anticancer Res 1994; 14: 1779–84.
- Shen H, Zhang M, Minuk GY, Gong Y. Different effects of rat interferon α, β and γ on rat hepatic stellate cell proliferation and activation. BMC Cell Biol 2002; 3: 9–16. CrossRef
- Platanias LC, Uddin S, Domanski P, Colamonici OR. Differences in interferon alpha and beta signaling. Interferon beta selectively induces the interaction of the α and βL subunits of the type I interferon receptor. J Biol Chem 1996; 271: 23630–3. CrossRef
- Russell-Harde D, Wagner TC, Perez HD, Croze E. Formation of a uniquely stable type I interferon receptor complex by interferon beta is dependent upon particular interactions between interferon beta and its receptor and independent of tyrosine phosphorylation. Biochem Biophys Res Commun 1999; 255: 539–44. CrossRef
- Chawla-Sarkar M, Leaman DW, Borden EC. Preferential induction of apoptosis by interferon (IFN)-beta compared with IFN-α2: correlation with TRAIL/Apo2L induction in melanoma cell lines. Clin Cancer Res 2001; 7: 1821–31.
- Qin XQ, Runkel L, Deck C, DeDios C, Barsoum J. Interferon-beta induces S phase accumulation selectively in human transformed cells. J Interferon Cytokine Res 1997; 17: 355–67. CrossRef
- Sangfelt O, Strander H. Apoptosis and cell growth inhibition as antitumor effector functions of interferons. Med Oncol 2001; 18: 3–14. CrossRef
- Jonasch E, Haluska FG. Interferon in oncological practice: review of interferon biology, clinical applications, and toxicities. Oncologist 2001; 6: 34–55. CrossRef
- Kreuser ED, Wadler S, Thiel E. Biochemical modulation of cytotoxic drugs by cytokines: molecular mechanisms in experimental oncology. Recent Results Cancer Res 1995; 139: 371–82.
- Makower D, Wadler S. Interferons as biomodulators of fluoropyrimidines in the treatment of colorectal cancer. Seminin Oncol 1999; 26: 663–71.
- Eguchi H, Nagano H, Yamamoto H, et al. Augmentation of antitumor activity of 5-fluorouracil by interferon alpha is associated with up-regulation of p27Kip1 in human hepatocellular carcinoma cells. Clin Cancer Res 2000; 6: 2881–90.
- Kondo M, Nagano H, Sakon M, et al. Expression of interferon alpha/beta receptor in human hepatocellular carcinoma. Int J Oncol 2000; 17: 83–8.
- Interferon-β Is More Potent Than Interferon-α in Inhibition of Human Hepatocellular Carcinoma Cell Growth When Used Alone and in Combination With Anticancer Drugs
Annals of Surgical Oncology
Volume 10, Issue 10 , pp 1184-1190
- Cover Date
- Print ISSN
- Online ISSN
- Additional Links
- Anticancer drug
- Cell proliferation
- Combination therapy
- Industry Sectors
- Author Affiliations
- 1. Department of Surgery and Clinical Oncology (E2), Graduate School of Medicine, Osaka University, Osaka, Japan
- 2. Department of Surgery and Clinical Oncology (E2), Graduate School of Medicine, Osaka University, 2-2, Yamadaoka, Suita, Osaka, 565-0871, Japan